CVALF.US Covalon Technologies Ltd

Healthcare Biotechnology USA Stocks
2.94 USD
Close of Nov 14, 2026
1.16 3.65
Market cap
USD 81.2M
P/E
24.5x
P/B
3.64x
ROE
17.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Jun 2026.

Is CVALF.US undervalued?

Graham number
Price2.94
Graham value1.48
Premium99.0%

CVALF.US trades 99.0% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Covalon Technologies Ltd fundamental analysis

No fundamental analysis for Covalon Technologies Ltd yet.

Covalon Technologies Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Covalon Technologies Ltd

Covalon Technologies Ltd. engages in the research, development, manufacturing, and marketing of medical products in infection management, advanced wound care, and surgical procedure areas in the United States, the Middle East, Canada, Latin America, Asia, and internationally. The company's platform technologies comprises collagen matrix platform that is used to manufacture a family of products to treat chronic and infected wounds, including diabetic ulcers, pressure ulcers, …

Full company profile